Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
MicroRNAs | 11 | 2021 | 301 | 4.570 |
Why?
|
Exosomes | 8 | 2021 | 96 | 3.750 |
Why?
|
Breast Neoplasms | 8 | 2019 | 459 | 2.840 |
Why?
|
Docosahexaenoic Acids | 7 | 2015 | 105 | 2.100 |
Why?
|
Clioquinol | 7 | 2011 | 11 | 1.870 |
Why?
|
Neoplasms | 9 | 2020 | 809 | 1.820 |
Why?
|
Cell Line, Tumor | 22 | 2021 | 1319 | 1.760 |
Why?
|
Signal Transduction | 7 | 2019 | 1435 | 1.480 |
Why?
|
Gene Expression Regulation, Neoplastic | 6 | 2019 | 465 | 1.390 |
Why?
|
Extracellular Vesicles | 2 | 2021 | 43 | 1.370 |
Why?
|
Zinc | 6 | 2014 | 63 | 1.220 |
Why?
|
Antineoplastic Agents | 6 | 2011 | 679 | 1.180 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 2 | 2018 | 9 | 1.170 |
Why?
|
Biomarkers, Tumor | 4 | 2019 | 405 | 1.130 |
Why?
|
Superoxide Dismutase | 5 | 2015 | 71 | 1.120 |
Why?
|
PPAR alpha | 3 | 2012 | 33 | 1.010 |
Why?
|
Protoporphyrins | 2 | 2015 | 12 | 0.900 |
Why?
|
beta Catenin | 2 | 2015 | 66 | 0.870 |
Why?
|
Proteolysis | 2 | 2015 | 58 | 0.860 |
Why?
|
Pancreatic Neoplasms | 4 | 2021 | 540 | 0.850 |
Why?
|
Lysosomes | 3 | 2015 | 56 | 0.850 |
Why?
|
Heme Oxygenase-1 | 2 | 2014 | 36 | 0.840 |
Why?
|
Humans | 35 | 2021 | 28097 | 0.780 |
Why?
|
Serine-Arginine Splicing Factors | 1 | 2020 | 5 | 0.700 |
Why?
|
Proteasome Inhibitors | 3 | 2015 | 26 | 0.660 |
Why?
|
Apoptosis | 5 | 2010 | 775 | 0.650 |
Why?
|
Drug Carriers | 1 | 2020 | 115 | 0.640 |
Why?
|
Molecular Targeted Therapy | 1 | 2020 | 135 | 0.630 |
Why?
|
Histone Deacetylases | 1 | 2019 | 26 | 0.610 |
Why?
|
Adenocarcinoma | 1 | 2021 | 298 | 0.610 |
Why?
|
Cell-Derived Microparticles | 2 | 2020 | 11 | 0.590 |
Why?
|
Repressor Proteins | 1 | 2019 | 118 | 0.580 |
Why?
|
Reactive Oxygen Species | 3 | 2015 | 285 | 0.570 |
Why?
|
Cell Communication | 2 | 2020 | 68 | 0.570 |
Why?
|
Ovarian Neoplasms | 3 | 2013 | 589 | 0.570 |
Why?
|
3' Untranslated Regions | 2 | 2015 | 34 | 0.570 |
Why?
|
Cell Survival | 7 | 2019 | 409 | 0.550 |
Why?
|
Blotting, Western | 6 | 2021 | 514 | 0.540 |
Why?
|
Female | 13 | 2021 | 15156 | 0.510 |
Why?
|
Heterogeneous-Nuclear Ribonucleoprotein D | 1 | 2015 | 4 | 0.480 |
Why?
|
Mice, Nude | 4 | 2021 | 331 | 0.480 |
Why?
|
Wnt Signaling Pathway | 1 | 2015 | 57 | 0.460 |
Why?
|
Chloroquine | 1 | 2014 | 9 | 0.460 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2015 | 94 | 0.460 |
Why?
|
Angiogenesis Inhibitors | 1 | 2015 | 109 | 0.450 |
Why?
|
Fanconi Anemia Complementation Group Proteins | 1 | 2014 | 4 | 0.440 |
Why?
|
Peroxiredoxin VI | 1 | 2014 | 1 | 0.440 |
Why?
|
Animals | 11 | 2021 | 10423 | 0.440 |
Why?
|
Basic-Leucine Zipper Transcription Factors | 1 | 2014 | 34 | 0.440 |
Why?
|
Protein Biosynthesis | 1 | 2014 | 111 | 0.430 |
Why?
|
RNA, Neoplasm | 1 | 2013 | 24 | 0.420 |
Why?
|
Thromboplastin | 2 | 2010 | 28 | 0.410 |
Why?
|
Wnt Proteins | 1 | 2013 | 34 | 0.410 |
Why?
|
Skin | 1 | 2014 | 149 | 0.400 |
Why?
|
Ionophores | 2 | 2009 | 6 | 0.400 |
Why?
|
Receptors, Gastrointestinal Hormone | 2 | 2002 | 3 | 0.390 |
Why?
|
Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2012 | 60 | 0.380 |
Why?
|
Nitroquinolines | 1 | 2011 | 2 | 0.370 |
Why?
|
Cell Line | 4 | 2019 | 696 | 0.350 |
Why?
|
Acetylcysteine | 1 | 2010 | 24 | 0.340 |
Why?
|
Copper | 1 | 2010 | 49 | 0.330 |
Why?
|
Nucleotide Motifs | 2 | 2020 | 20 | 0.330 |
Why?
|
Hydrogen Peroxide | 1 | 2010 | 144 | 0.330 |
Why?
|
Glutathione Peroxidase | 2 | 2007 | 26 | 0.330 |
Why?
|
Transcription, Genetic | 2 | 2009 | 403 | 0.320 |
Why?
|
Metals | 1 | 2009 | 41 | 0.320 |
Why?
|
Superoxide Dismutase-1 | 4 | 2015 | 51 | 0.310 |
Why?
|
Xenograft Model Antitumor Assays | 3 | 2019 | 269 | 0.300 |
Why?
|
Basic Helix-Loop-Helix Transcription Factors | 1 | 2009 | 54 | 0.300 |
Why?
|
CRISPR-Cas Systems | 2 | 2019 | 48 | 0.300 |
Why?
|
Base Sequence | 3 | 2020 | 586 | 0.300 |
Why?
|
Lipid Peroxidation | 4 | 2014 | 47 | 0.300 |
Why?
|
Down-Regulation | 2 | 2004 | 199 | 0.270 |
Why?
|
Gene Expression Regulation | 3 | 2020 | 632 | 0.260 |
Why?
|
Disease Progression | 2 | 2018 | 473 | 0.260 |
Why?
|
Cyclic AMP | 2 | 2003 | 87 | 0.250 |
Why?
|
Reproducibility of Results | 2 | 2020 | 769 | 0.240 |
Why?
|
Neoplasm Invasiveness | 2 | 2018 | 190 | 0.230 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 3 | 2013 | 328 | 0.230 |
Why?
|
Aged, 80 and over | 2 | 2021 | 2021 | 0.220 |
Why?
|
Proteasome Endopeptidase Complex | 2 | 2015 | 80 | 0.210 |
Why?
|
Colforsin | 1 | 2003 | 12 | 0.210 |
Why?
|
Islets of Langerhans | 1 | 2003 | 9 | 0.210 |
Why?
|
Vascular Endothelial Growth Factor A | 2 | 2015 | 179 | 0.200 |
Why?
|
Cyclic AMP-Dependent Protein Kinases | 1 | 2003 | 33 | 0.200 |
Why?
|
Mice | 4 | 2021 | 4654 | 0.200 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2006 | 409 | 0.200 |
Why?
|
Gastrinoma | 1 | 2002 | 3 | 0.190 |
Why?
|
Biological Transport | 2 | 2015 | 122 | 0.190 |
Why?
|
Receptors, Cholecystokinin | 1 | 2002 | 5 | 0.190 |
Why?
|
RNA Splicing | 1 | 2002 | 9 | 0.190 |
Why?
|
Introns | 1 | 2002 | 43 | 0.190 |
Why?
|
Microscopy, Electron | 1 | 2021 | 94 | 0.190 |
Why?
|
Circulating MicroRNA | 1 | 2021 | 10 | 0.190 |
Why?
|
Tumor Cells, Cultured | 4 | 2004 | 315 | 0.180 |
Why?
|
Insulin | 1 | 2003 | 315 | 0.180 |
Why?
|
Endothelial Cells | 2 | 2015 | 352 | 0.180 |
Why?
|
Ribonucleoproteins | 1 | 2002 | 154 | 0.180 |
Why?
|
Carcinoma, Pancreatic Ductal | 1 | 2002 | 138 | 0.170 |
Why?
|
Gene Expression | 2 | 2002 | 417 | 0.170 |
Why?
|
Microscopy, Fluorescence | 2 | 2013 | 163 | 0.170 |
Why?
|
Nuclear Proteins | 1 | 2002 | 247 | 0.160 |
Why?
|
Protein Transport | 2 | 2015 | 158 | 0.160 |
Why?
|
Fish Oils | 1 | 2019 | 12 | 0.160 |
Why?
|
MCF-7 Cells | 1 | 2019 | 34 | 0.160 |
Why?
|
Gene Knockout Techniques | 1 | 2019 | 35 | 0.160 |
Why?
|
Aged | 2 | 2021 | 5400 | 0.160 |
Why?
|
RNA, Nuclear | 1 | 2019 | 3 | 0.160 |
Why?
|
Gene Ontology | 1 | 2019 | 12 | 0.160 |
Why?
|
Cell Hypoxia | 1 | 2019 | 35 | 0.150 |
Why?
|
Tamoxifen | 1 | 2019 | 33 | 0.150 |
Why?
|
Green Fluorescent Proteins | 1 | 2019 | 101 | 0.150 |
Why?
|
Protein Binding | 1 | 2020 | 658 | 0.150 |
Why?
|
Drug Screening Assays, Antitumor | 2 | 2011 | 103 | 0.150 |
Why?
|
DNA Primers | 2 | 2013 | 147 | 0.150 |
Why?
|
Genes, jun | 1 | 1998 | 3 | 0.150 |
Why?
|
Trans-Activators | 1 | 2019 | 118 | 0.150 |
Why?
|
RNA, Small Interfering | 2 | 2013 | 198 | 0.150 |
Why?
|
Receptors, Muscarinic | 1 | 1998 | 9 | 0.150 |
Why?
|
Genes, fos | 1 | 1998 | 13 | 0.150 |
Why?
|
Transduction, Genetic | 1 | 1998 | 27 | 0.150 |
Why?
|
Caspase 3 | 2 | 2010 | 58 | 0.150 |
Why?
|
Drug Delivery Systems | 1 | 2020 | 225 | 0.140 |
Why?
|
Middle Aged | 2 | 2021 | 7138 | 0.140 |
Why?
|
Promoter Regions, Genetic | 2 | 2014 | 343 | 0.140 |
Why?
|
Drug Synergism | 2 | 2009 | 104 | 0.140 |
Why?
|
Chelating Agents | 2 | 2009 | 22 | 0.140 |
Why?
|
Cell Movement | 1 | 2019 | 373 | 0.140 |
Why?
|
Dietary Supplements | 1 | 2019 | 254 | 0.130 |
Why?
|
Culture Media, Conditioned | 1 | 2016 | 31 | 0.130 |
Why?
|
Heterografts | 1 | 2016 | 66 | 0.130 |
Why?
|
NF-kappa B | 2 | 2008 | 191 | 0.130 |
Why?
|
Nanoparticles | 1 | 2020 | 287 | 0.130 |
Why?
|
Neoplasm Grading | 1 | 2016 | 104 | 0.130 |
Why?
|
Proto-Oncogene Proteins c-akt | 2 | 2008 | 155 | 0.130 |
Why?
|
ROC Curve | 1 | 2016 | 144 | 0.130 |
Why?
|
Prognosis | 1 | 2018 | 803 | 0.130 |
Why?
|
Cell Proliferation | 1 | 2019 | 806 | 0.130 |
Why?
|
Catalase | 2 | 2007 | 49 | 0.120 |
Why?
|
rab27 GTP-Binding Proteins | 1 | 2015 | 5 | 0.120 |
Why?
|
RNA, Messenger | 3 | 2002 | 659 | 0.120 |
Why?
|
Neoplasm Staging | 1 | 2016 | 478 | 0.120 |
Why?
|
rab GTP-Binding Proteins | 1 | 2015 | 33 | 0.120 |
Why?
|
Gene Knockdown Techniques | 1 | 2015 | 134 | 0.120 |
Why?
|
Case-Control Studies | 1 | 2016 | 722 | 0.110 |
Why?
|
Neovascularization, Physiologic | 1 | 2015 | 124 | 0.110 |
Why?
|
Antioxidant Response Elements | 1 | 2014 | 5 | 0.110 |
Why?
|
Gene Expression Profiling | 1 | 2016 | 453 | 0.110 |
Why?
|
Fluorescent Dyes | 1 | 2014 | 92 | 0.110 |
Why?
|
Radiation, Ionizing | 1 | 2014 | 25 | 0.110 |
Why?
|
Radiation Tolerance | 1 | 2014 | 28 | 0.110 |
Why?
|
Phosphorylation | 1 | 2015 | 578 | 0.110 |
Why?
|
Genes, Reporter | 1 | 2013 | 87 | 0.100 |
Why?
|
NF-E2-Related Factor 2 | 1 | 2014 | 122 | 0.100 |
Why?
|
Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2012 | 11 | 0.100 |
Why?
|
Transcriptome | 1 | 2014 | 214 | 0.100 |
Why?
|
Alternative Splicing | 2 | 2002 | 47 | 0.100 |
Why?
|
Cloning, Molecular | 2 | 2002 | 208 | 0.100 |
Why?
|
Tumor Microenvironment | 1 | 2013 | 178 | 0.090 |
Why?
|
Receptors, G-Protein-Coupled | 2 | 2002 | 77 | 0.090 |
Why?
|
HL-60 Cells | 1 | 2011 | 22 | 0.090 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2010 | 607 | 0.090 |
Why?
|
Disease Models, Animal | 1 | 2016 | 1461 | 0.090 |
Why?
|
Poly(ADP-ribose) Polymerases | 1 | 2010 | 22 | 0.090 |
Why?
|
Amino Acid Sequence | 2 | 2002 | 692 | 0.080 |
Why?
|
Rats | 1 | 2014 | 1576 | 0.080 |
Why?
|
Microscopy, Confocal | 1 | 2010 | 113 | 0.080 |
Why?
|
Molecular Sequence Data | 2 | 2002 | 1054 | 0.080 |
Why?
|
Protease Inhibitors | 1 | 2009 | 40 | 0.080 |
Why?
|
Clofibrate | 1 | 2009 | 4 | 0.080 |
Why?
|
Cathepsin D | 1 | 2009 | 3 | 0.080 |
Why?
|
Ammonium Chloride | 1 | 2009 | 4 | 0.080 |
Why?
|
Intracellular Membranes | 1 | 2009 | 15 | 0.080 |
Why?
|
Thiones | 1 | 2009 | 55 | 0.080 |
Why?
|
Cell Membrane Permeability | 1 | 2009 | 44 | 0.080 |
Why?
|
Ligands | 1 | 2009 | 176 | 0.080 |
Why?
|
Pyridines | 1 | 2009 | 107 | 0.080 |
Why?
|
Triazenes | 1 | 2008 | 2 | 0.080 |
Why?
|
Ethylenediamines | 1 | 2008 | 2 | 0.080 |
Why?
|
Mutation | 1 | 2012 | 847 | 0.070 |
Why?
|
Inhibitory Concentration 50 | 1 | 2007 | 34 | 0.070 |
Why?
|
Regression Analysis | 1 | 2007 | 210 | 0.070 |
Why?
|
Vitamin E | 1 | 2006 | 11 | 0.070 |
Why?
|
Transcription Factor RelA | 1 | 2006 | 21 | 0.060 |
Why?
|
Cisplatin | 1 | 2007 | 179 | 0.060 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2006 | 68 | 0.060 |
Why?
|
Male | 1 | 2021 | 13491 | 0.060 |
Why?
|
Coagulants | 1 | 2005 | 7 | 0.060 |
Why?
|
Annexin A5 | 1 | 2005 | 24 | 0.060 |
Why?
|
Mitochondria | 1 | 2009 | 369 | 0.060 |
Why?
|
Cell Growth Processes | 1 | 2005 | 18 | 0.060 |
Why?
|
Protein Structure, Tertiary | 2 | 2005 | 284 | 0.060 |
Why?
|
Caspases | 1 | 2005 | 43 | 0.060 |
Why?
|
Glyceraldehyde-3-Phosphate Dehydrogenases | 1 | 2004 | 5 | 0.060 |
Why?
|
Recombinant Fusion Proteins | 1 | 2005 | 233 | 0.060 |
Why?
|
Blood Coagulation | 1 | 2005 | 118 | 0.060 |
Why?
|
Cattle | 1 | 2005 | 388 | 0.050 |
Why?
|
Anticoagulants | 1 | 2005 | 294 | 0.050 |
Why?
|
Flavonoids | 1 | 2003 | 32 | 0.050 |
Why?
|
Secretin | 1 | 2002 | 2 | 0.050 |
Why?
|
Vasoactive Intestinal Peptide | 1 | 2002 | 5 | 0.050 |
Why?
|
COS Cells | 1 | 2002 | 49 | 0.050 |
Why?
|
Dimerization | 1 | 2002 | 76 | 0.050 |
Why?
|
CHO Cells | 1 | 2002 | 96 | 0.050 |
Why?
|
Mitogen-Activated Protein Kinases | 1 | 2003 | 87 | 0.050 |
Why?
|
Cricetinae | 1 | 2002 | 129 | 0.050 |
Why?
|
Cell Division | 1 | 2002 | 154 | 0.050 |
Why?
|
Protein Isoforms | 1 | 2002 | 119 | 0.050 |
Why?
|
Splicing Factor U2AF | 1 | 2002 | 1 | 0.050 |
Why?
|
MAP Kinase Signaling System | 1 | 2003 | 95 | 0.050 |
Why?
|
Receptor, Cholecystokinin B | 1 | 2002 | 8 | 0.050 |
Why?
|
Exons | 1 | 2002 | 42 | 0.050 |
Why?
|
DNA, Complementary | 1 | 2002 | 78 | 0.050 |
Why?
|
Enzyme Inhibitors | 1 | 2003 | 250 | 0.050 |
Why?
|
Transfection | 1 | 2002 | 318 | 0.040 |
Why?
|
Muscarine | 1 | 1998 | 1 | 0.040 |
Why?
|
Genes, Immediate-Early | 1 | 1998 | 5 | 0.040 |
Why?
|
Muscarinic Agonists | 1 | 1998 | 9 | 0.040 |
Why?
|
Carbachol | 1 | 1998 | 18 | 0.040 |
Why?
|
Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1998 | 31 | 0.040 |
Why?
|
Protein Kinase C | 1 | 1998 | 73 | 0.040 |
Why?
|
Calcium | 1 | 1998 | 235 | 0.030 |
Why?
|
Adult | 1 | 2002 | 7740 | 0.020 |
Why?
|
Factor VIIIa | 1 | 2005 | 2 | 0.020 |
Why?
|
Factor X | 1 | 2005 | 11 | 0.020 |
Why?
|
Phosphatidylserines | 1 | 2005 | 20 | 0.020 |
Why?
|
Heparin, Low-Molecular-Weight | 1 | 2005 | 35 | 0.020 |
Why?
|
Blood Vessels | 1 | 2005 | 59 | 0.010 |
Why?
|
Neovascularization, Pathologic | 1 | 2005 | 149 | 0.010 |
Why?
|
Hemorrhage | 1 | 2005 | 265 | 0.010 |
Why?
|